AC Immune reported key progress in Q1 2026, including dosing the first subjects in a Phase 1 trial of its NLRP3 inhibitor ACI-19764 and initiating the final cohort in its Phase 1b/2 ABATE trial for Alzheimer's treatment ACI-24, triggering a $12 million milestone from Takeda. The company also amended its collaboration with Eli Lilly on Tau-targeting small molecules and presented promising interim data on its Parkinson's immunotherapy ACI-7104. With CHF 74.8 million cash, AC Immune is funded into Q4 2027 and anticipates multiple data readouts and IND-enabling studies throughout 2026, marking significant steps toward new neurodegenerative disease therapies.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
